Nuron Biotech selects Merck BioManufacturing Network
NU100 is a proprietary recombinant human interferon beta compound under development as a potential treatment for multiple sclerosis (MS) and will go into Phase III clinical trials in
Biologics contract development and manufacturing organisation (CDMO) AsymBio is set to secure 1.2397bn yuan (approximately $184m) from Asymchem Group, Hillhouse Qirui and other investors to support its long-term growth.